Navigation Links
Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
Date:3/27/2009

SHENZEN, China, March 27 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Today after the market closed the company announced the clinical trial protocol for their MMR Vaccine is under preparation, and is expected to be approved by the end of the second quarter 2009.

The MMR Vaccine is a mixture of three live attenuated viruses administered via injection for immunization against measles, mumps, and rubella (also called German measles). It is generally administered to children around the age of one year, with a second dose before starting school (i.e. age 4/5).

Prior to the widespread use of a vaccine against measles, its incidence was so high that infection was felt to be inevitable. Today, it is widely used around the world, and since introduction of its earliest versions in the 1970s, more than 500 million doses have been administered in over 60 countries. The incidence rate has fallen to a low of less than 1% of people under the age of 30 in countries with routine childhood vaccination.

The company will provide further details as they become available.

Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.

CONTACT: For medical and scientific dialogue inquiry only, please contact medicalinfo@htdsmedical.com; For any corporate matters, readers should contact the company directly at corporate@htdsmedical.com


'/>"/>
SOURCE Hard to Treat Diseases
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Microsurgery May Cut Swelling After Breast Cancer Treatment
2. Treatment Target for Herpes Pinpointed
3. Plastic Surgeon Allan Parungao, MD, FACS, Announces Clinical Trial of Juvderm Technique to Treat Root Cause of Midface Sagging, without Surgery
4. Individualized stroke treatment available for patients, though underutilized
5. New Guidelines for Treating Heart Failure
6. New OTC Allergy Treatment Available to Food Allergy Sufferers
7. Combating weight gain caused by antipsychotic treatments
8. Autism Study Finds Significant Benefit with Hyperbaric Treatment
9. NeuroVasx Receives CE Mark for cPAX Aneurysm Treatment System
10. Surveyed Experts Indicate that Biogen Idecs Adentri Has Advantages Over Nitroglycerin in the Treatment of Acute Heart Failure
11. Autism Website Relaunches to Offer Resources, Treatments and Hope for Families
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)... , ... May 22, 2017 , ... An inventor from ... with a pen. "My wife’s hand was damaged in a firework accident, so she ... helps people with manual problems." , He then designed and created a prototype for ...
(Date:5/22/2017)... ... ... Galena, Alaska, has a population of less than 500 people. But, the little, ... build a nuclear plant by the TOSHIBA Corporation. , In “The Galena Nuclear Project: ... journey to get power to his small town, off the electrical grid. , “We ...
(Date:5/22/2017)... Francisco, CA (PRWEB) , ... May 22, 2017 ... ... will sponsor a program on Wellocity to empower WeightZone Factor members to ... their medications, and get an excellent health education, all on their mobile phones. ...
(Date:5/21/2017)... ... ... was found dead on the night of Wednesday, May 17, 2017. It can be difficult ... industry would take his own life, but the extremely talented and admired singer and ... in the death of Chris Cornell . , Depression and Drug Use , Cornell ...
(Date:5/21/2017)... ... May 20, 2017 , ... GetLinked® software ... and financial systems. , Dozens of clubs using ABC Financial Services are ... through GetLinked into their club’s accounting system , The latest implementation is ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... COTTAGE, N.Y. , May 22, 2017 /PRNewswire/ ... antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of a ... plain English, the results of a clinical study ... one year treatment with Gene-Eden-VIR/Novirin in individuals suffering ... important to note that there are no other ...
(Date:5/18/2017)... N.J. , May 18, 2017  Two Bayer ... Businesswomen,s Association (HBA) during its recent 28 th ... York City.  The event showcases HBA,s longstanding mission of ... business of healthcare. Cindy Powell-Steffen , ... Bayer,s U.S. Radiology division, and Libby Howe , ...
(Date:5/15/2017)... 15, 2017  Amy Baxter MD, chief executive officer ... noninvasive pain relief, was awarded a 2017 Top 40 ... was recognized at the MM&M Top 40 Healthcare Transformers ... on May 10, 2017. The dinner followed ... go "beyond the pill."  "Innovation goes beyond ...
Breaking Medicine Technology: